domingo, 28 de julio de 2019

Elon Musk and his neurotech start-up are trialling brain-decoding implants

Elon Musk and his neurotech start-up are trialling brain-decoding implants

Bioedge

Elon Musk and his neurotech start-up are trialling brain-decoding implants
     
US entrepreneur Elon Musk and his tech start-up Neuralink have unveiled a new brain monitoring device that could one day enable paraplegics to use their thoughts to operate computers and smartphones. 
The new technology is based around a "sewing machine" robot that will be used to implant thousands of electrodes into the brain to monitor and stimulate neural activity.
Musk hosted an evening event earlier this month at the California Academy of Sciences where he and his team provided an overview of their research.
In theory, the new device could allow a computer system to detect and analyze brain activity in a way that translates into outputs such as “move a robotic arm 3 inches up and left and grab what’s there”. It could also stimulate the somatosensory cortex in a way that would make paralyzed patients feel as though they had touched something.
Experts have been impressed by the progress of the ambitious project. “Overall, the concept is impressive and so is the progress they’ve made,” said neurobiologist Andrew Schwartz of the University of Pittsburgh Medical Center, a pioneer in the technology. 
Yet there is still much work to be done. “A lot of this still seems to be conceptual”, Schwartz said. “It’s hard to tell what’s aspirational and what they’ve actually done”. 
There are significant concerns about the durability of the technology, and its potential to damage the brain. 
In his presentation, Musk has alluded to the fact that the electrodes implanted in the brain will eventually stop working and require replacement. Removal of the electrodes could be difficult, as they are attached to remarkably thin electrode-holding threads. 
There are also risks that the implants could cause trigger infection, or be the catalyst for a stroke, aneurysm or immune reaction in the patient. 
“The big risk, of course, is if something goes wrong… one more major adverse event could cause a stricter regulatory crackdown,” said Andrew Hires, a neurobiologist at the University of Southern California, whose research focuses on how the brain processes the sense of touch and emotion in the cortex.
Even still, Neuralink has said that it hopes to start tests on human subjects as early as next year. 
Xavier Symons is deputy editor of BioEdge

Bioedge

What's in a name? Does it make a difference if (by way of example) the widespread abortion of unborn children with Down syndrome is called "eugenics"? A number of bioethicists deny that it is, even though the rates of termination reach 90% if a diagnosis is made before birth. From their point of view, "eugenics" is a word reserved for Nazi atrocities. The destruction of children with Down syndrome is not being carried out by Nazis, ergo, it is not eugenics.

A number of bioethicists writing from a disability perspective disagree. We have presented some of their arguments in a special issue of the Journal of Policy and Practice in Intellectual Disabilities. They have a refreshingly different opinion on this contentious topic.

 
m.png
Michael Cook
Editor
BioEdge
 Comment on BioedgeFind Us on FacebookFollow us on Twitter
NEWS THIS WEEK
by Michael Cook | Jul 28, 2019
Yes, say experts in disability care 
 
 
by Michael Cook | Jul 28, 2019
Very little has been written 
 
 
by Michael Cook | Jul 28, 2019
Some freed provided that they raise children as their own 
 
 
by Michael Cook | Jul 28, 2019
Identity of patient kept secret 
 
 
by Michael Cook | Jul 28, 2019
Despite the headlines, it could be a statistical glitch 
 
 
by Michael Cook | Jul 28, 2019
Scottish study shows that 1 in 6 will conceive without artificial means 
 
 
by Xavier Symons | Jul 28, 2019
The researchers want to start trials on humans next year    
Bioedge

BioEdge
Level 1, 488 Botany Road, Alexandria NSW 2015 Australia
Phone: +61 2 8005 8605
Mobile: 0422-691-615

No hay comentarios: